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Volume 52, Number 6 Abstracts 1735cefepime) group, 13% in the vancomycin cephalosporin group; and 6% in
the daptomycin  cefepime group (P  .01). The frequency of MRSA SSI
was similar (P .1) in patients receiving daptomycin (1.3%) compared to the
other prophylactic antibiotic regimens (4.8%). Overall, 41 (73%) of 56
patients with SSI required surgical therapy to achieve wound healing with
mean LOS increase of 12 days in SSI group. Outcomes at 30 days included
1.3% (4 patients) mortality and one prosthetic graft excised for infection.
Diabetes was associated with increased SSI (P  .04) while age, gender,
CAD, BMI, or renal insufficiency were not predictive of SSI.
Conclusions. This audit demonstrated one in seven patients devel-
ops SSI after arterial intervention involving the femoral artery. SSI risk
was higher in diabetics, after arterial bypass, with required therapeutic
antibiotics, and when nasal MRSA colonization was present. The most
common bacterial isolate was MRSA. The addition of a single-dose of
daptomycin (bactericidal to gram  organism including MRSA) to a
cephalosporin prophylaxis regimen significantly reduced SSI. Given the
trend to mandated hospital reporting of wound infection rates to con-
sumers, these SSI statistics are relevant and indicate an urgent need to
develop wound care strategies to augment primary healing and the
prevention of biofilm-mediated infection.
The Role of Statin Therapy and Angiotensin Blockade on Asymptom-
atic Moderate Carotid Artery Stenosis: A Clinical and Pharacoeco-
nomic Analysis
Christopher A. Durham, Bryan A. Ehlert, Steven C. Agle, Ashley C. Mays,
Frank M. Parker, William M. Bogey, Charles S. Powell, Michael C. Stoner,
East Carolina University, Greenville, NC
Introduction: Although the algorithm for symptomatic and severe
carotid disease is less controversial, questions remain as to the optimal
approach toward asymptomatic moderate carotid artery stenosis. The aim
of this study is to evaluate the 10-year outcome of patients presenting
with asymptomatic moderate carotid artery stenosis and to determine
which factors correlate with progression of disease to stroke or revascu-
larization.
Methods: A retrospective review of all new patients presenting with
asymptomatic moderate carotid artery stenosis from July 1998 to December
2001 was undertaken. Variables were recorded for all patient encounters
occurring through June 2010. A novel endpoint for a stroke or revascular-
ization event was defined:
● SORE - occurrence of ipsilateral cerebrovascular event or carotid revascu-
larization
Statin therapy and angiotensin blockade (STAB) were categorized as fol-
lows:
● STAB0 - Medical treatment with neither statin therapy nor angiotensin
blockade
● STAB1 - Medical treatment with only one of these therapies
● STAB2 - Medical treatment employing both therapies
To evaluate relative cost effectiveness of STAB therapy, an amortized model
based on our previously described cost efficacy model was used to analyze
the cost of each year without SORE.
Results: Over a 42-month period, 468 carotids in 366 patients were
evaluated for asymptomatic moderate carotid artery stenosis. The average
age of the entire cohort was 68.7 years, with a predominance of hyperten-
sion, coronary artery disease, hyperlipidemia, and smoking history. The
contralateral carotid was noted to have a greater than 50% stenosis in 68.0%
of patients. Antiplatelet therapy was employed in the treatment of 84.5% of
patients, compared to statin therapy in 63.5% and angiotensin blockade in
48.3% of patients. Over a mean follow-up of 6.6 years, SORE occurred in
150 (32.1%) carotid arteries. Cases were then stratified by occurrence of
SORE. Cases without SORE were noted to have a higher rate of bilateral
stenosis greater than 50%. Antiplatelet, statin, and angiotensin blockade
were found in significantly lower rates in cases progressing to SORE.
Multivariate analysis revealed only hyperlipidemia was predictive of SORE
(HR 1.524, CI 1.039-2.236, P  .03). Medical therapy with either a statin
or angiotensin blockade (STAB1) was protective against SORE (HR 0.505,
CI 0.350-0.730, P .01), and the additive effects of both statin therapy and
angiotensin pathway blockage (STAB2) were even more pronounced (HR
0.147, CI 0.089-0.244, P  .01). Bilateral stenosis greater than 50%
continued to be protective (HR 0.420, CI 0.302-0.584, P  .01) against
SORE. At 10 years, SORE-free survival was achieved in STAB2 in
82.7  4.6%. In STAB1, 56.3  5.0% had no SORE. The STAB0 cohort
had 29.3  5.4%without SORE (P .01). The cost model revealed the cost
per SORE-free year in the STAB2 cohort to be $1695.40  $275.60, less
than 50% that of either STAB1 ($3916.80  605.44) or STAB0
($4126.40  427.23) therapy (P  .01).Conclusion: These data are the first to demonstrate the clinical and
financial advantage of using both statin therapy and angiotensin pathway
blockage in patients with asymptomatic moderate carotid artery stenosis.
Avoidance of stroke and progression to surgery in these patients, with
concurrent cost savings, implies that this strategy should be standard of care
in this at-risk population.
Trends, Charges, and Outcomes in Endovascular Therapy for Periph-
eral Arterial Disease in Florida
Michael S. Hong, Khayree Butler, Trevan D. Fischer, Peter R. Nelson,
University of Florida, Gainesville, Fla
Background: We sought to define the current trends in the use of
endovascular procedures and the impact on the associated costs and
outcomes in Florida. These data can then be used as a baseline assessment
for the development of a statewide cooperative quality improvement
program.
Methods: The Agency for Healthcare Administration (AHCA) data-
base, which contains 100% of discharges from Florida hospitals, was queried
for peripheral arterial disease (PAD) from 2000 to 2008. Discharges from
ambulatory centers were also available from 2004 to 2008 allowing more
comprehensive analysis of endovascular procedures. Angioplasty, atherec-
tomy, and peripheral stents were identified either by respective CPT codes
for ambulatory procedures, or ICD-9 procedure codes for hospital-based
procedures, comprising the endovascular group. The open bypass group was
identified using ICD-9 codes for hospital data. Major amputations (above
knee to ankle), and minor amputations (forefoot to toe) were identified.
Total charges, including a breakdown of component charges, were com-
pared between groups.
Results: Lower extremity bypass procedures decreased 31% from
2000 to 2008 from 5294 to 3636. Hospital based endovascular inter-
ventions increased 113% during the same time points from 2698 to 5748.
Endovascular interventions performed at ambulatory centers showed a
121% increase in just 5 years from 2004 to 2008 (3014 vs 6670*).
Combined hospital and ambulatory based endovascular therapy exceeded
open bypass procedures by over threefold in 2008 (12,419 vs 3636) (Fig
1). Consistent with previous administrative database studies, major am-
putations decreased consistently each year, resulting in a 43% decrease
from 2000 to 2008 (2833 vs 1609), whereas minor amputations were
stable (1354 vs 1362). Total charges were highest for open bypass
($62,946  65,595), followed by hospital based endovascular proce-
dures ($57,995  58,008), and lowest for ambulatory endovascular
procedures ($32,719  16,574) (Table). Comparing specific charges for
hospital based endovascular vs open bypass procedures, higher charges
for medical/surgical supplies and radiology for endovascular procedures
was offset by savings in anesthesia, as well as shorter length of stay as
reflected in smaller charges for ICU/floor, medications, and laboratory
studies. Endovascular procedures at ambulatory centers had substantially
lower charges overall and in all of the major categories. Notably, among
over 20,000 discharges from ambulatory centers, there were two deaths,
and only 10 were transferred to inpatient care.
Conclusion: In Florida, rapid adoption of endovascular procedures,
particularly in ambulatory centers, has led to a decrease in open bypass
procedures and is associated with a continual decrease in major amputations.
For carefully selected patients, endovascular procedures performed in am-
bulatory centers are safe and offer significant cost savings. These data provide
the platform for a prospective, collaborative Florida Vascular Study Group
aimed at prospective quality improvement. * Projected 2008 ambulatory
data based on the first three quarters due to lack of Q4 data at the time of
submission
Table. Total and component charges by type of
procedure and setting
Open
bypass
Endovascular
(hospital)
Endovascular
(ambulatory)
Total charges $61,946 $57,995 $32,719
ICU/floor $ 7547 $ 4806 n/a
Medications/lab
studies
$14,466 $10,574 $ 1622
Medical/surgical
supply
$ 9559 $14,095 $11,151
Radiology
Studies/therapy
$ 3106 $ 8887 $ 7219
OR charges $13,922 $ 9854 $ 8905
Anesthesia charges $ 3487 $ 1007 $ 219
Recovery/observation $ 2025 $ 2183 $ 1176
Other $ 7834 $ 6589 $ 2427
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December 20101736 AbstractsEndovascular Retrieval of a Permanent IVC Filter placed within the
Aorta
Sailen G. Naidu, William M. Stone, John P. Sweeney, Samuel R. Money,
Mayo Clinic Arizona, Phoenix, Ariz
Background: Intra-aortic IVC filter placement is exceptionally rare.
Treatment options include observation, open removal and endovascular
retrieval. We describe an endovascular retrieval of a permanent IVC filter
from the aorta.
Methods:A 43-year-old male was referred for consultation regarding a
permanent inferior vena cava filter (Trapease) inadvertently placed within
the aorta at an outside institution. This filter has side struts present superiorly
and inferiorly to prevent migration. An additional filter was placed into the
inferior vena cava. The patient presented 6 weeks later without symptoms.
He had been placed on warfarin therapy. A 16F sheath was inserted into the
right femoral artery via surgical cut down. A percutaneous left brachial artery
8F long sheath was placed. A Venture catheter was used to hook the superior
apex of the filter and a floppy .014” wire advanced with its tip was pointed in
the cephalad direction. The wire was snared and bought back through the 8F
sheath such that the wire was looped through the apex with both ends
exiting the brachial sheath. From below, a similar technique was used. An
11F sheath was placed through the 16F sheath. The inferior apex of the filter
was hooked, and the wire snared such that both ends of the wire were exiting
the 11F sheath (Fig 1). With wire access gained from above and below,
gentle traction was held on the wires to elongate the filter, release the struts
from the wall of the aorta and to prevent movement of the filter (Fig. 2).
While maintaining traction, the 8F sheath was advanced over the filter
covering the superior struts. The 11F sheath was advanced over the inferior
struts and the 8F sheath from below in an intussesception fashion. From
below, the filter and wires were removed. Completion aortogram was
performed.
Results: Aortogram showed no abnormality in the aorta. The patient
was placed on Plavix for 3 months.
Conclusions: The long-term sequelae of intraaortic IVC filter place-
ment is not established. Endovascular retrieval of an intraaortic permanent
filter can be performed safely with proper planning and understanding of
filter strut design.Stent-Assisted Coiling of Carotid Aneurysm with Symptomatic Steno-
sis Under Embolic Protection with Flow Reversal
Carlos H. Timaran, Eric B. Rosero, J. Gregory Modrall, G. Patrick Clagett,
University of Texas Medical Center, Dallas, Tex
Background: Carotid stenting is an established treatment option for
carotid lesions, particularly when these are inaccessible to surgical repair.
Stent-assisted coiling has expanded the treatment of carotid aneurysms, but
this novel treatment requires embolic protection for aneurysms associated
with symptomatic stenoses. Because of the inability to deploy a filter device
distal to lesions near the skull base, either proximal balloon occlusion or flow
reversal devices may be required for cerebral embolic protection. We report
a case of an internal carotid artery aneurysm associated with a symptomatic
stenosis near the skull base successfully treated with stent-assisted coiling
under embolic protection using flow reversal.
Methods and results: A 78-year old male presented with amaurosis
fugax. Duplex ultrasound revealed no stenosis at the level of the carotid
bifurcation. MR and CT angiograms (CTA) revealed a fusiform aneurysm of
the right internal carotid artery just proximal to the petrous portion at the
skull base (26 mm in diameter). An area of severe stenosis just proximal to
the aneurysm was also noted (Fig1). Because of the symptomatic nature of
this complex carotid lesion, endovascular treatment under local anesthesia
using embolic protection with flow reversal with the GORE Neuro Protec-
tion System (NPS; W.L. Gore and Associates, Flagstaff, AZ) was performed.
After carotid and cerebral angiogram were obtained, the balloon sheath was
advanced into the proximal internal carotid artery (ICA). The balloon wire
for the external carotid artery (ECA) was not used since the balloon sheath
was advanced beyond the carotid bifurcation. Instead, a microcatheter was
advanced through the ECA port into the aneurysm sac. Under flow reversal,
the carotid lesion was crossed using a 0.014-inch guidewire. Predilatation
with a 4  20 mm balloon angioplasty catheter was performed. Then, two
Cordis Precise stents (Cordis, Warren, NJ) (7  40 mm and 7  30 mm)
were deployed excluding the carotid lesion. Stent-assisted coiling of the
aneurysm sac was then performed using the previously placed microcatheter
with platinum detachable coils (eV3, Irvine, CA) (Fig 2). Subsequent
angiogram and intravascular ultrasound confirmed complete expansion and
apposition of the stents and obliteration of the aneurysm. Flow reversal was
terminated and distal flow restored. The patient remained neurologically
intact throughout the entire procedure and tolerated flow reversal satisfac-
torily. Postoperative CTAs at 1 and 6 months confirmed complete obliter-
ation of the aneurysm and widely patent stents. The patient remains asymp-
tomatic at 6 months follow-up.
Conclusion: Stent-assisted coiling is a reasonable option for the treat-
ment of a symptomatic carotid aneurysm with stenosis inaccessible to open
repair. Because carotid lesions near the skull base preclude the use of a filter
device, flow reversal may effectively provide cerebral embolic protection
throughout the entire stent-assisted coiling procedure.
